GlassScriptPhysician profile
Rachel Katter
NPI 1013596337
$3,032.84
in general payments reported to CMS, 2019-2025
26 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $209 · 2023: $501 · 2024: $846 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,631 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,631.49 |
| Education | $192.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $394.63 | 2023-2025 | |
| Janssen Biotech, INC. | $347.57 | 2024-2025 | Rybrevant, Carvykti, Erleada |
| Daiichi Sankyo INC. | $305.66 | 2024-2025 | Enhertu, Datroway |
| Puma Biotechnology, INC. | $258.88 | 2022-2025 | |
| Gilead Sciences, INC. | $248.81 | 2023-2025 | Trodelvy |
| Lilly USA, LLC | $187.07 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Merck Sharp & Dohme LLC | $176.61 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech, INC. | $145.53 | 2024 | Phesgo, Tecentriq, Avastin |
| Pfizer INC. | $124.58 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $116.40 | 2024-2025 | Opdualag |
| Stemline Therapeutics INC. | $84.05 | 2023-2025 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $78.88 | 2023-2025 | Enhertu |
| Tersera Therapeutics LLC | $73.70 | 2022-2025 | Zoladex |
| Mirati Therapeutics, INC. | $68.70 | 2023-2024 | Krazati |
| Genentech USA, INC. | $67.75 | 2023-2025 | Itovebi, Phesgo, Erivedge |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $67.20 | 2022-2023 | Tivdak, Tukysa |
| Amgen INC. | $50.22 | 2022-2023 | Nplate, Xgeva, Vectibix |
| Incyte Corporation | $42.87 | 2024-2025 | Monjuvi, Pemazyre |
| Beone Medicines USA, INC. | $40.59 | 2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $30.46 | 2024 | Ultomiris |
| Exelixis INC. | $26.17 | 2023 | Cabometyx |
| Genzyme Corporation | $22.55 | 2022 | |
| Jazz Pharmaceuticals INC. | $21.05 | 2025 | |
| Springworks Therapeutics, INC. | $18.87 | 2024 | Ogsiveo |
| Genmab U.S., INC. | $17.28 | 2024 | Epkinly |
| Caris Mpi, INC. | $16.76 | 2025 | Mi Cancer Seek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Katter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.